News | Lung Cancer | July 16, 2018

Study Shows Biomarker Panel Boosts Lung Cancer Risk Assessment for Smokers

Blood test can extend reach of CT screening beyond those with heavy smoking history

Study Shows Biomarker Panel Boosts Lung Cancer Risk Assessment for Smokers

July 16, 2018 — A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history. The blood test captures risk for people who have ever smoked, not only for heavy smokers, an international research team reports in JAMA Oncology.

“This simple blood test demonstrates the potential of biomarker-based risk assessment to improve eligibility criteria for lung cancer screening with low-dose computed tomography,” said study co-senior author Sam Hanash, M.D., Ph.D., professor of clinical cancer prevention at The University of Texas MD Anderson Cancer Center.

The biomarker panel achieved superior sensitivity – identification of smokers who later developed lung cancer – without increasing false-positives compared to guidelines for screening approved by the U.S. Preventive Service Task Force (USPSTF) for heavy smokers based on age and smoking history.

USPSTF guidelines call for computed tomography (CT) screening only of adults between ages 55 and 80 with a 30 pack-year smoking history who either smoke or have quit within the past 15 years.

“The biomarker panel more accurately identifies at-risk smokers who should proceed to screening, even if they’re not at the highest risk based on smoking history alone,” Hanash said. “A positive blood test means an ever-smoker is as much, if not more so, at risk of having lung cancer as a heavy smoker with a low biomarker score.”

The paper reports a validation study of the biomarker model in 63 ever-smoking patients who developed lung cancer within a year of initial blood sample collection compared to 90 matched controls in two large European population-based cohorts.

Researchers compared a model based on smoking history to an integrated model that included the biomarker score based on the four markers plus smoking history.

At the same level of false-positive rate (specificity) set by the USPSTF guidelines, the integrated test with biomarkers identified 63 percent of future lung cancer cases (40 of 63), compared to 42 percent (20 of 62) based on smoking history alone.

The improved detection rate, Hanash said, reflects the biomarker panel’s ability to identify at-risk people among the larger population of ever-smokers. In the validation study, smoking history did not improve prediction of future lung cancer cases beyond that provided by the biomarkers alone.

Hanash said the key to selecting the biomarkers was the availability of blood samples taken from people before they had developed the disease. This contrasts to most previous studies comparing biomarkers in early-stage lung cancer patients to healthy controls. Such studies do not reflect how biomarkers can help to predict future cancers.

To develop the biomarker blood test, Hanash’s group led the analysis of blood samples taken from 108 ever-smokers who went on to be diagnosed with lung cancer within a year of sampling, compared to 216 smoking-matched controls. All were participants in the Carotene and Retinol Efficacy Trial (CARET), a lung cancer prevention trial conducted in North America in the 1990s.

“We compared smokers with lung cancer to smokers who didn’t have lung cancer, and we showed there are biomarker differences between those groups, so it wasn’t only smoking status giving us differences,” Hanash said. “Then we compared cancer cases to the general population and found similar differences.”

The resulting panel includes four proteins found in the blood:

  • The precursor form of surfactant protein B (Pro-SFTPB);
  • Cancer antigen 125 (CA125);
  • Cytokeratin-19 fragment (CYFRA 21-1); and
  • Carcinoembryonic antigen (CEA).

The validation study was conducted among patients from the European Prospective Investigation into Cancer and Nutrition and the Northern Sweden Health and Disease Study.

The researchers note that their findings need to be validated in larger studies to further validate and fine-tune the biomarker-based prediction model. Hanash said that will depend upon guidance from the U.S. Food and Drug Administration (FDA), and consultations with the FDA have begun.

Lung cancer causes an estimated 20-25 percent of all deaths from cancer — 1.69 million annually worldwide and 155,000 in the United States. Early detection improves prospects of survival, but most countries do not screen for the disease and it’s estimated that fewer than half of all U.S. cases are among people who are eligible under USPSTF guidelines.

For more information: www.jamanetwork.com/journals/jamaoncology

Reference

Guida F., Sun N., Bantis L.E., et al. "Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins." JAMA Oncology, July 12, 2018. doi:10.1001/jamaoncol.2018.2078

Related Content

Stereotactic Radiosurgery Effective for Pediatric Arteriovenous Malformation Patients
News | Radiation Therapy | April 19, 2019
Ching-Jen Chen, M.D., of the neurosurgery department at the University of Virginia (UVA) Health System, was the winner...
Video Plus Brochure Helps Patients Make Lung Cancer Scan Decision

Image courtesy of the American Thoracic Society

News | Lung Cancer | April 19, 2019
A short video describing the potential benefits and risks of low-dose computed tomography (CT) screening for lung...
FDA Clears GE's Deep Learning Image Reconstruction Engine
Technology | Computed Tomography (CT) | April 19, 2019
GE Healthcare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) of its Deep Learning Image...
Artificial Intelligence Performs As Well As Experienced Radiologists in Detecting Prostate Cancer
News | Artificial Intelligence | April 18, 2019
University of California Los Angeles (UCLA) researchers have developed a new artificial intelligence (AI) system to...
Videos | Breast Imaging | April 18, 2019
In a keynote lecture at the Society of Breast Imaging (SBI)/American College of Radiology (ACR) 2019 Symposium, ...
Surgically Guided Brachytherapy Improves Outcomes for Intracranial Neoplasms
News | Brachytherapy Systems | April 18, 2019
Peter Nakaji, M.D., FAANS, general practice neurosurgeon at Barrow Neurological Institute, presented new research on...
Oxipit Introduces Multilingual Support for ChestEye AI Imaging Suite
News | Artificial Intelligence | April 16, 2019
The CE-certified ChestEye artificial intelligence (AI) imaging suite by Oxipit is now available in seven European...
Check-Cap Initiates U.S. Pilot Study of C-Scan for Colorectal Cancer Screening
News | Colonoscopy Systems | April 15, 2019
Check-Cap Ltd. has initiated its U.S. pilot study of the C-Scan system for prevention of colorectal cancer through...
Deep Lens Closes Series A Financing for Digital AI Pathology Platform
News | Digital Pathology | April 09, 2019
Digital pathology company Deep Lens Inc. announced the closing of a $14 million Series A financing that will further...
Enlitic Closes Series B Funding for Artificial Intelligence Solutions for Radiologists
News | Artificial Intelligence | April 08, 2019
Radiology artificial intelligence (AI) company Enlitic announced the close of its $15 million Series B financing round...